Loteprednol etabonate gel 0.5% for postoperative pain and inflammation after cataract surgery: results of a multicenter trial

PURPOSE: Loteprednol etabonate (LE) is approved by the US FDA in a suspension and ointment form (0.5%) for the treatment of postoperative ocular inflammation. This study examined the gel formulation of LE, an improved, nonsettling formulation with a lower preservative level and a more physiologic pH...

Descripción completa

Detalles Bibliográficos
Autores principales: Fong, Raymond, Leitritz, Martin, Siou-Mermet, Raphaele, Erb, Tara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3413337/
https://www.ncbi.nlm.nih.gov/pubmed/22888209
http://dx.doi.org/10.2147/OPTH.S32643

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3413337/
https://www.ncbi.nlm.nih.gov/pubmed/22888209
http://dx.doi.org/10.2147/OPTH.S32643

Ejemplares similares